Stoke therapeutics, inc. (STOK)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19
Cash flows from operating activities:
Net loss

-11,039

-10,160

-8,604

-7,819

-5,742

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation

193

139

126

105

80

Stock-based compensation

754

712

731

298

181

Loss on disposal of property and equipment

-3

0

0

0

-3

Reduction in the carrying amount of right of use assets

253

-

-

-

-

Changes in assets and liabilities:
Prepaid expenses and other current assets

924

-863

1,866

225

796

Accounts payable and accrued liabilities

-11

-1,761

1,557

1,360

-265

Deferred rent

-

6

8

7

7

Net cash used in operating activities

-10,771

-10,201

-8,048

-6,274

-6,532

Cash flows from investing activities:
Purchases of property and equipment

610

568

583

392

92

Proceeds from sale of property and equipment

-

-1

0

0

2

Net cash used in investing activities

-610

-569

-583

-392

-90

Cash flows from financing activities:
Payments on capital lease

1

-

-

-

1

Proceeds from issuance of common stock upon exercise of stock options

199

194

19

28

74

Deferred Financing Costs

-

-

-

-

141

Net cash provided by (used in) financing activities

198

192

-1,000

150,638

-68

Net decrease in cash, cash equivalents and restricted cash

-11,183

-10,578

-9,631

143,972

-6,690

Supplemental Disclosure of Non-Cash Investing and Financing Activities:
Property and equipment included in accrued expense and accounts payable

35

-

-

38

198

Right-of-use assets recognized in exchange for operating leases upon adoption of Topic 842

2,153

-

-

-

-

Deferred offering costs not yet paid

-

-

-

77

944